Discover why combining tissue NGS, ctDNA and IHC uncovers actionable NSCLC biomarkers, shaping first-line therapy, resistance, and new ADC options.
Back
Optimizing Biomarker-Driven Management in NSCLC: Focus on STK11, MTAP, TROP2, EGFR, KRAS, and MET
Dr. Eric Singhi (MD Anderson) and Dr. Chinmay Jani (University of Miami) as they explore biomarker-driven management in advanced NSCLC. The session emphasizes best practices in biomarker testing, optimal timing, tissue-based versus ctDNA approaches, and the value of repeat testing at progression, while addressing real-world institutional barriers to comprehensive molecular profiling. The experts dissect how key biomarkers inform treatment sequencing and decision-making, including KRAS mutation subtypes and their therapeutic implications, STK11 and MTAP as modifiers of immunotherapy response, the evolution of EGFR resistance, and emerging targets such as TROP2. The discussion also covers unmet needs, notably MET amplification as a resistance mechanism after osimertinib and how serial liquid biopsies and complex genomic patterns may be integrated into clinical choice. Tailored for community and academic oncologists and multidisciplinary teams, the program aims to sharpen precision biomarker strategies in everyday practice for better patient outcomes.
Optimizing Biomarker-Driven Management in NSCLC: Focus on STK11, MTAP, TROP2, EGFR, KRAS, and MET
Episodes
All
All
Experts explain combining tissue NGS, ctDNA liquid biopsy and IHC to uncover actionable NSCLC biomarkers and guide first-line targeted therapy.
Experts unpack NGS, ctDNA and protein testing to speed actionable biomarker detection and guide targeted therapy choices in advanced lung cancer.
See how KRAS mutations, especially G12C, guide NSCLC treatment sequencing—from PD-L1 strategy to sotorasib/adagrasib and emerging trials.
Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.
Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.
How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.
Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.
Explore NSCLC precision oncology gaps: expand targets beyond EGFR, refine liquid biopsies and MRD, and fix incomplete NGS testing.
Learn why paired tissue and liquid NGS at diagnosis and progression uncovers actionable NSCLC alterations, guiding trials and future monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL
2
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma
3
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
4
Dr Van Gorp on PFS Data With TUB-040 in Platinum-Resistant Ovarian Cancer
5